Production (Stage)
X4 Pharmaceuticals, Inc.
XFOR
$3.10
-$0.13-4.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 100.71% | -8.52% | -140.40% | 275.47% | -170.60% |
| Total Depreciation and Amortization | 74.36% | 2.25% | 37.63% | 212.90% | 0.00% |
| Total Amortization of Deferred Charges | 11.94% | 3.61% | -6.28% | -18.50% | 2.42% |
| Total Other Non-Cash Items | -295.33% | 33.51% | 103.15% | -877.51% | 541.66% |
| Change in Net Operating Assets | -374.25% | 172.09% | -258.30% | -49.86% | 139.01% |
| Cash from Operations | 62.52% | 3.05% | -12.40% | 9.88% | -21.08% |
| Capital Expenditure | -- | 55.43% | 31.34% | -127.12% | -68.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 63.43% | 45.82% | -97.86% | -52.08% | -9.69% |
| Cash from Investing | 63.60% | 45.88% | -116.45% | 1,920.03% | -10.12% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | -- | -- |
| Foreign Exchange rate Adjustments | 129.51% | -247.88% | 1,016.67% | 69.49% | -146.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 63.01% | 16.21% | -157.42% | 322.50% | -20.47% |